NEW YORK (GenomeWeb) –  Bioinformatics software provider Genialis has raised $2.3 million in a recently closed seed round that was co-led by Zurich, Switzerland-based Redalpine Venture Capital and Boston's First Star Venture Capital.

Other investors in the round include Slovenian firm Pikas as well as several unnamed angel investors, according to Genialis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.